Analyst Tracker/Mitchell Kapoor

Mitchell Kapoor

Q: How accurate are Mitchell Kapoor's stock ratings?

About 44% of Mitchell's ratings were profitable over a one-year hold, with an average return of -1.1% per rating, measured by 13Foresight from historical prices.

Q: How is Mitchell ranked?

Mitchell Kapoor is ranked #2206 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★★☆☆

#2206

on 13Foresight · ranked by our own returns

44%

Success Rate

-1.3%

Average Return

100 of 229 calls profitable · -103.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 44% of Mitchell Kapoor's ratings turned a profit when each position was held for 1 year — averaging -1.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

262 Buy 45 Hold 15 Sell

Mitchell's Stock Coverage 44 ratings · 2026-11-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
GENB Generate Biomedicines, Inc.	Oct 30, 2026	BUY	Strong Buy +85.4% avg upside 6 analysts	$30.00 107.53% Upside	-16.5%	·
LEGN Legend Biotech	Oct 30, 2026	BUY	Strong Buy +182.3% avg upside 27 analysts	$65.00 200.57% Upside	-19.1%	·
SRPT Sarepta Therapeutics	Oct 30, 2026	SELL	Buy +223.8% avg upside 50 analysts	$5.00 73.23% Downside	+13.9%	·
INCY Incyte	Oct 30, 2026	BUY	Buy -5.9% avg upside 49 analysts	$152.00 26.31% Upside	+1.1%	·
PALI Palisade Bio	Oct 29, 2026	BUY	Strong Buy +2087.9% avg upside 16 analysts	$7.00 503.55% Upside	-5.9%	·
EVMN Evommune, Inc.	Oct 29, 2026	HOLD	Strong Buy +283.4% avg upside 13 analysts	—	+12.0%	·
SE:SOBI Swedish Orphan Biovitrum AB	Oct 28, 2026	BUY	Strong Buy -7.0% avg upside 7 analysts	$600.00 22.46% Upside	+1.8%	·
RNA Atrium Therapeutics, Inc.	Oct 28, 2026	BUY	Strong Buy +246.7% avg upside 6 analysts	$20.00 141.90% Upside	-10.7%	·
NGNE Neurogene	Oct 28, 2026	BUY	Buy +79.4% avg upside 24 analysts	$65.00 135.85% Upside	-22.1%	·
CBIO Crescent Biopharma	Oct 27, 2026	BUY	Strong Buy +73.7% avg upside 17 analysts	$36.00 167.15% Upside	+2.0%	·
LYEL Lyell Immunopharma	Oct 27, 2026	BUY	Buy +151.1% avg upside 12 analysts	$45.00 307.57% Upside	+41.3%	·
SMMT Summit Therapeutics	Oct 27, 2026	HOLD	Buy +83.4% avg upside 29 analysts	—	-7.7%	·
ORKA Oruka Therapeutics	Oct 27, 2026	BUY	Strong Buy +37.2% avg upside 16 analysts	$120.00 23.92% Upside	+9.7%	·
KYTX Kyverna Therapeutics, Inc.	Oct 26, 2026	BUY	Strong Buy +382.0% avg upside 8 analysts	$25.00 340.95% Upside	-8.0%	·
IONS Ionis Pharmaceuticals	Oct 26, 2026	BUY	Strong Buy +74.1% avg upside 44 analysts	$100.00 129.71% Upside	-28.6%	·
AVTX Avalo Therapeutics	Oct 23, 2026	HOLD	Strong Buy +561.5% avg upside 20 analysts	$30.00 318.51% Upside	+12.0%	·
KRRO Korro Bio	Oct 23, 2026	BUY	Strong Buy +90.0% avg upside 19 analysts	$15.00 4.76% Upside	+13.5%	·
ASND Ascendis Pharma	Oct 19, 2026	BUY	Strong Buy +12.2% avg upside 29 analysts	$344.00 36.81% Upside	+19.8%	·
HALO Halozyme	Oct 16, 2026	BUY	Strong Buy -48.1% avg upside 20 analysts	$130.00 0.75% Downside	-17.7%	·
CRSP Crispr Therapeutics AG	Oct 09, 2026	BUY	Buy +45.6% avg upside 41 analysts	$80.00 55.51% Upside	-20.9%	·
GLUE Monte Rosa Therapeutics	Oct 05, 2026	BUY	Strong Buy +108.5% avg upside 16 analysts	$25.00 132.34% Upside	-8.8%	·
ALMS Alumis Inc.	Oct 05, 2026	BUY	Strong Buy +361.9% avg upside 11 analysts	$15.00 122.89% Upside	-18.1%	·
RNAC Cartesian Therapeutics	Sep 30, 2026	BUY	Strong Buy +378.5% avg upside 19 analysts	$25.00 285.17% Upside	-4.4%	·
TYRA Tyra Bioscience	Sep 22, 2026	BUY	Strong Buy +107.4% avg upside 17 analysts	$29.00 37.69% Upside	-21.7%	·
BMRN BioMarin Pharmaceutical	Sep 10, 2026	HOLD	Strong Buy +63.6% avg upside 52 analysts	$60.00 2.54% Upside	-12.6%	·
NTLA Intellia Therapeutics	Sep 09, 2026	BUY	Buy +187.2% avg upside 39 analysts	$25.00 100.48% Upside	-20.6%	·
SCTX Scribe Therapeutics Inc.	Sep 03, 2026	BUY	Strong Buy +235.6% avg upside 4 analysts	$60.00 289.06% Upside	-49.0%	·
MGTX Meiragtx Holdings	Aug 14, 2026	BUY	Strong Buy +166.7% avg upside 14 analysts	$20.00 110.82% Upside	-32.1%	·
IPSC Century Therapeutics	Aug 13, 2026	BUY	Buy +262.2% avg upside 11 analysts	$5.00 240.21% Upside	-14.5%	·
DMRA Damora Therapeutics	Aug 11, 2026	BUY	Strong Buy +39.9% avg upside 20 analysts	$45.00 109.45% Upside	-21.9%	·
EDIT Editas Medicine	Aug 06, 2026	BUY	Buy +398.5% avg upside 33 analysts	$5.00 87.29% Upside	-25.2%	·
CTMX CytomX Therapeutics	May 11, 2026	BUY	Strong Buy +361.2% avg upside 21 analysts	$11.00 370.19% Upside	-47.1%	·
LXEO Lexeo Therapeutics, Inc.	Jan 13, 2026	BUY	Strong Buy +528.2% avg upside 11 analysts	$10.00 218.39% Upside	-61.4%	·
TIL Instil Bio	Jan 08, 2026	HOLD	Buy +389.0% avg upside 8 analysts	—	-17.7%	·
BOLD Boundless Bio Inc.	Oct 24, 2025	BUY	Hold +264.4% avg upside 11 analysts	$4.00 61.98% Upside	+61.6%	·
MGX Metagenomi, Inc.	Oct 22, 2025	BUY	Strong Buy +1032.0% avg upside 8 analysts	$7.00 796.99% Upside	-71.7%	·
ZURA Zura Bio	Aug 19, 2025	HOLD	Strong Buy +292.3% avg upside 13 analysts	$2.00 50.43% Downside	+237.6%	·
GYRE Gyre Therapeutics	Aug 11, 2025	BUY	Strong Buy +354.4% avg upside 15 analysts	$25.00 448.76% Upside	-6.1%	·
RLYB Rallybio	Apr 30, 2025	HOLD	Buy +51.4% avg upside 8 analysts	—	+250.8%	·
CARM Carisma Therapeutics	Apr 04, 2025	HOLD	Buy +584900.0% avg upside 11 analysts	—	·	·
RANI Rani Therapeutics Holdings	Apr 03, 2025	BUY	Strong Buy +1444.2% avg upside 10 analysts	$9.00 1425.42% Upside	-35.4%	·
ABEO Abeona Therapeutics	Mar 21, 2025	BUY	Strong Buy +295.1% avg upside 18 analysts	$15.00 244.91% Upside	-13.6%	·
OKUR OnKure Therapeutics	May 14, 2024	HOLD	Buy +743.5% avg upside 13 analysts	$15.00 472.53% Upside	-88.7%	·
ADTX Aditxt	Sep 06, 2023	BUY	Strong Buy +15249900.0% avg upside 2 analysts	$61.00 15249900.03% Upside	·	·

🔒 39 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Mitchell Kapoor — Frequently Asked Questions

How accurate are Mitchell Kapoor's stock ratings?

Based on the calls 13Foresight could measure, about 44% of Mitchell's ratings were profitable over a one-year hold, with an average return of -1.1% per rating, or -103.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Mitchell ranked on 13Foresight?

Mitchell Kapoor is currently ranked #2206 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Mitchell cover?

Mitchell most recently has ratings on GENB, LEGN, SRPT, INCY, PALI, EVMN, SE:SOBI, RNA, NGNE, CBIO, LYEL, SMMT and 32 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Mitchell Kapoor

Rating Distribution

Welcome to 13Foresight!